CHLOROPTIC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CHLOROPTIC (CHLOROPTIC).
Chloroptic (chloramphenicol) inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
| Metabolism | Primarily hepatic metabolism via glucuronidation; minor metabolism by reduction to aryl amines. |
| Excretion | Primarily renal elimination (70-80% as unchanged drug). Minor biliary/fecal excretion (<10%). |
| Half-life | Terminal elimination half-life is approximately 2-4 hours in patients with normal renal function, necessitating frequent dosing (every 4-6 hours) to maintain therapeutic levels. |
| Protein binding | 20-40% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | 0.15-0.25 L/kg, indicating distribution mainly into extracellular fluid. |
| Bioavailability | Topical ophthalmic: low systemic bioavailability (<10%) due to drainage and dilution by tears, with clinical effects largely local. |
| Onset of Action | Ophthalmic: 5-15 minutes after instillation. |
| Duration of Action | Ophthalmic: 4-6 hours, supporting a dosing regimen of every 4-6 hours. |
| Molecular Weight | 323.13 |
1 drop (0.5% solution) into the affected eye(s) every 4-6 hours.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | 1 drop (0.5% solution) into the affected eye(s) every 4-6 hours in children ≥2 years. |
| Geriatric use | Same as adult dosing; monitor for local adverse effects. |
| 1st trimester | No adequate studies in pregnant women. Use only if potential benefit justifies risk. Avoid prolonged use. |
| 2nd trimester | Use only if clearly needed. Consider potential risk of systemic effects. |
| 3rd trimester | Avoid use near term due to possible association with neonatal hypotension, hypothermia, and flaccidity. |
Clinical note
Comprehensive clinical and safety monograph for CHLOROPTIC (CHLOROPTIC).
| Placental transfer | Chloramphenicol crosses the placenta and achieves fetal serum concentrations approximately 30-80% of maternal levels. |
| Breastfeeding | Chloroptic (chloramphenicol) is excreted in breast milk. Potential risk of bone marrow suppression in nursing infants. Contraindicated in breastfeeding due to serious adverse effects. |
■ FDA Black Box Warning
Serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia, granulocytopenia) have been reported after topical ophthalmic use.
| Serious Effects |
Hypersensitivity to chloramphenicol or any componentFamily history of blood dyscrasiasPrevious chloramphenicol-induced bone marrow depressionPorphyriaBreastfeedingNewborns (especially premature) due to gray baby syndrome
| Precautions | Bone marrow suppression; avoid prolonged use; monitor blood counts if repeated courses; do not use for trivial infections. |
| Food/Dietary | No significant food interactions. Avoid alcohol consumption as it may increase risk of side effects. |
Loading safety data…
| Lactation Rating |
| Avoid |
| Teratogenic Risk | Topical ophthalmic chloramphenicol (CHLOROPTIC) has minimal systemic absorption, but due to theoretical risks, use during pregnancy is not recommended unless clearly necessary. First trimester: Potential association with aplastic anemia in offspring (theoretical). Second and third trimesters: Theoretical risk of gray baby syndrome if high systemic levels occur (unlikely with topical use). |
| Fetal Monitoring | Monitor for signs of bone marrow suppression (e.g., unexplained bruising, bleeding, infection) in the mother and infant if prolonged therapy is required. Routine complete blood count (CBC) monitoring is advisable. |
| Fertility Effects | There are no known adverse effects of ophthalmic chloramphenicol on human fertility. Animal studies have not shown impaired fertility. |
| Clinical Pearls |
| CHLOROPTIC (chloramphenicol ophthalmic solution) is effective for bacterial conjunctivitis but carries risk of aplastic anemia with systemic absorption; use only for topical ocular infections and avoid prolonged use. Monitor for signs of bone marrow suppression if used extensively. |
| Patient Advice | Apply 1-2 drops in the affected eye(s) every 2-4 hours for the first 48 hours, then decrease frequency as directed. · Do not touch the dropper tip to any surface, including the eye, to avoid contamination. · Complete the full course of treatment even if symptoms improve. · Notify your doctor immediately if you experience unusual bleeding, bruising, or signs of infection such as fever or sore throat. · Remove contact lenses before use and wait at least 15 minutes before reinserting. |